



HAL
open science

Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of β -glycoprotein I (apolipoprotein H)

Haider Mehdi, Asma Naqvi, M. Liyas Kamboh

► To cite this version:

Haider Mehdi, Asma Naqvi, M. Liyas Kamboh. Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of β -glycoprotein I (apolipoprotein H). *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 2008, 10.1016/j.bbadis.2008.01.001 . hal-00562817

HAL Id: hal-00562817

<https://hal.science/hal-00562817>

Submitted on 4 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of β_2 – glycoprotein I (apolipoprotein H)

Haider Mehdi, Asma Naqvi, M. Ilyas Kamboh

PII: S0925-4439(08)00013-6
DOI: doi: [10.1016/j.bbadis.2008.01.001](https://doi.org/10.1016/j.bbadis.2008.01.001)
Reference: BBADIS 62778

To appear in: *BBA - Molecular Basis of Disease*

Received date: 31 August 2007
Revised date: 4 December 2007
Accepted date: 2 January 2008



Please cite this article as: Haider Mehdi, Asma Naqvi, M. Ilyas Kamboh, Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of β_2 – glycoprotein I (apolipoprotein H), *BBA - Molecular Basis of Disease* (2008), doi: [10.1016/j.bbadis.2008.01.001](https://doi.org/10.1016/j.bbadis.2008.01.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of β_2 -glycoprotein I (apolipoprotein H)

Running Title: Binding of rHBsAg and Anionic PL to β_2 GPI

Haider Mehdi*, Asma Naqvi and M. Ilyas Kamboh

Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA

Abbreviation: Hepatitis B virus, HBV; Hepatitis B surface antigen, HBsAg; Recombinant, r; Phospholipid, PL; β_2 -Glycoprotein I, β_2 GPI; Apolipoprotein H, apoH; Antiphospholipid antibodies, APA; Cardiolipin, CL

*Present address and address for correspondence:

H. Mehdi, Ph.D., Cardiovascular Institute, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA (E-mail: mehdih@upmc.edu) or M.I. Kamboh, Department of Human Genetics, Graduate School of Public Health, 130 DeSoto Street, University of Pittsburgh, Pittsburgh, PA 15261, USA (E-mail: ikamboh@hgen.pitt.edu)

Abstract

Human β_2 -glycoprotein I (β_2 GPI) binds to recombinant hepatitis B surface antigen (rHBsAg), but the location of the binding domain on β_2 GPI is unknown. It has been suggested that the lipid rather than the protein moiety of rHBsAg binds to β_2 GPI. Since β_2 GPI binds to anionic phospholipids (PL) through its lipid binding region in the fifth domain of β_2 GPI, we predicted that this lipid binding region may also be involved in binding rHBsAg. In this study, we examined rHBsAg binding to two naturally occurring mutants of β_2 GPI, Cys306Gly and Trp316Ser, or evolutionarily conserved hydrophobic amino acid sequence, Leu313-Ala314-Phe315 in the fifth domain of β_2 GPI. The two naturally occurring mutations and two mutagenized amino acids, Leu313Gly or Phe315Ser, disrupted the binding of recombinant β_2 GPI (r β_2 GPI) to both rHBsAg and cardiolipin (CL), an anionic PL. These results suggest that rHBsAg and CL share the same region in the fifth domain of β_2 GPI. Credence to this conclusion was further provided by competitive ELISA, where CL-bound r β_2 GPI was incubated with increasing amounts of rHBsAg. As expected, pre-incubation of r β_2 GPI with CL precluded binding to rHBsAg, indicating that CL and rHBsAg bind to the same region on β_2 GPI. Our data provide evidence that the lipid (PL) rather than the protein moiety of rHBsAg binds to β_2 GPI and that this binding region is located in the fifth domain of β_2 GPI, which also binds to anionic PL.

Keywords: Hepatitis B surface antigen; β_2 -Glycoprotein I; Apolipoprotein H; Anionic phospholipids

1. Introduction

Hepatitis B virus (HBV) belongs to a DNA-containing small enveloped hepadnavirus family, which includes woodchuck hepatitis virus [1], ground squirrel hepatitis virus [2], duck hepatitis B virus [3], and heron hepatitis virus [4]. These viruses infect and replicate primarily in hepatocytes *in vivo* and often lead to chronic infection in the cells of their respective hosts [5]. However, the mode of entry for HBV into the human hepatocytes or the HBV receptor is not well established. Several potential candidates for HBV receptor have been reported, including a 50 kDa glycoprotein known as β_2 -glycoprotein I (β_2 GPI) [6,7]. β_2 GPI, also known as apolipoprotein H, is a plasma glycoprotein [8], which is associated with very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), low-density lipoprotein (LDL) and chylomicrons, and it also exists in lipid-free form in plasma [9,10]. Furthermore, β_2 GPI shows higher binding with oxidized LDL than native LDL [11-13]. Mature β_2 GPI is a single chain polypeptide of 326 amino acids [14-17] and belongs to the short consensus repeats (SCR) or complement control protein (CCP) superfamily consisting of five homologous repeats (~60 amino acids each) referred to as: GP-I domains, Sushi domains, SCRs or SSP repeats. There are 22 cysteine residues in human β_2 GPI, which are conserved in bovine, rat, mouse and dog [18-21]. The first four GP-I domains (~60 amino acids each) are structurally related, while the fifth domain (84 amino acids) is the most variable and includes a cluster of lysine residues (282-287), four highly conserved hydrophobic amino acids (313-316), and three disulfide bonds instead of two as in each of the preceding four domains. Previously, we demonstrated that the β_2 GPI cDNA transfected COS-1 cells expressed and secreted full-length recombinant β_2 GPI (r β_2 GPI) into its

culture medium that exhibits normal binding to recombinant hepatitis B surface antigen (rHBsAg) [6]. We have also demonstrated that carbohydrate side chains and arginine residues of β_2 GPI have no effect on its ability to bind to rHBsAg, but this binding was disrupted by the reduction of disulfide bonds and by the chemical modification of as few as three lysine residues [7]. Since the fifth domain of β_2 GPI has a cluster of lysine residues (282-287) and three disulfide bonds, it was predicted to contain the binding site for rHBsAg.

Using either artificial mixtures of lipids [10] or pure lipids [22] it was originally suggested that ionic and hydrophobic interactions play major roles in the binding of β_2 GPI with phospholipids (PL). The binding of β_2 GPI with anionic PL triggers the production of a subset antiphospholipid antibodies (APA) in autoimmune diseases [23,24]. Several natural mutations have been reported in the β_2 GPI gene, including Ser88Asn, Val247Leu, Cys306Gly, and Trp316Ser [25-27]. The two mutations in the fifth domain of β_2 GPI, Cys306Gly and Trp316Ser, may be important because Cys306Gly disrupts one of the disulfide bonds and Trp316Ser disrupts the integrity of a cluster of hydrophobic amino acids at positions 313-316 (Leu-Ala-Phe-Trp), which are evolutionarily conserved in bovine, rat, mouse, dog, and human β_2 GPI [18-21]. Previously, we demonstrated that the Cys306Gly and Trp316Ser mutations disrupt the binding of plasma β_2 GPI [27] and r β_2 GPI [28] to anionic PL. By site-directed mutagenesis, we have also shown that in addition to Trp316, Leu313 and Phe315 are required for r β_2 GPI-PL binding [28].

Since the binding of β_2 GPI to rHBsAg is also dependent on the integrity of disulfide bond(s) and some lysine residues whose locations are not known [6,7], we

hypothesized that rHBsAg would bind to the same region in the fifth domain of β_2 GPI that is involved in binding anionic PL. To examine this hypothesis, we mutagenized the fifth domain of β_2 GPI and determined the effect of these mutations on its ability to bind rHBsAg compared to PL. We also performed a competition assay in an attempt to discriminate between the binding of rHBsAg and anionic PL to r β_2 GPI. Our results show that rHBsAg and anionic PL compete for the same binding region on r β_2 GPI.

2. Materials and Methods

2.1. Site-Directed Mutagenesis

Previously described cloned β_2 GPI cDNA in eukaryotic expression vector (pRc/CMV, Invitrogen) [16] was used to create the desired mutations using the QuickChange Site-Directed Mutagenesis kit (Stratagene) as described earlier [28]. Briefly, two mutagenic primers containing the desired mutation in the middle were used to PCR amplify the entire recombinant plasmid with *Pfu* DNA polymerase to mutate the β_2 GPI cDNA. For each mutagenesis experiments, four to eight colonies were grown in 5 ml of LB media containing ampicillin at 37°C for 16 h. The plasmid DNA was extracted by the Spin Plasmid Miniprep kit (Qiagen) and sequenced by chain-termination dideoxynucleosides methods [29] using Sequenase Version 2.0 DNA Sequencing kit (United States Biochemical) to confirm the mutation as well as the fidelity of *Pfu* DNA polymerase.

2.2. Transient Expression of r β_2 GPI

COS-1 cells were maintained as a monolayer in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS) (HyClone), 2

mM glutamine, 100 u/ml penicillin, and 100 µg/ml streptomycin at 37°C under 5% CO₂. Subconfluent monolayer of the cells grown overnight in 60 mm dishes were transiently transfected with wild type and mutant type β₂GPI cDNA by DEAE-dextran method as described earlier [28, 30]. After 48 hrs of transfection, cells were washed twice with phosphate-buffer-saline (PBS) and incubated for an additional 4-12 h in serum-free culture media to collect the secreted rβ₂GPI.

2.3. Detection of rβ₂GPI by Capture ELISA

The rβ₂GPI levels were detected by modified capture ELISA [6]. Briefly, 50 µl of anti-β₂GPI monoclonal antibody (mAb) (Chemicon International, Inc.) (5-7 µg/ml in PBS) was adsorbed onto 96 well vinyl microtiter plates (Costar) by overnight incubation at 4°C with a cover to prevent evaporation. The wells were washed three times with PBS and blocked with PBS containing 1 % bovine serum albumin (BSA) at 37°C for 90 minutes. Fifty µl of serum-free-cell-free culture media from the transfected COS-1 cells containing rβ₂GPI was added to the mAb-coated wells in triplicate followed by polyclonal rabbit anti-β₂GPI antiserum (Alexis Corp.) (0.5 µg/ml in PBS containing 1% BSA) and then by alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 minutes followed by addition of 100 µl of para-nitrophenyl phosphate (PNP) substrate (Chemicon International, Inc.). The wells were washed three times with PBS between each incubation for all binding assays. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.

2.4. Binding of r β_2 GPI to rHBsAg

The r β_2 GPI captured on anti- β_2 GPI mAb coated wells were incubated with 2.5 μ g of rHBsAg (rS,L* particles was produced in *Saccharomyces cerevisiae* [31,32]) diluted in PBS containing 1% BSA at 22°C for 16 hrs [6]. The bound rHBsAg was then detected by goat anti-hepatitis B surface antigen (anti-HBs) antiserum (OAKO Corp.) followed by alkaline phosphatase-conjugated rabbit anti-goat IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 minutes followed by addition of 100 μ l of PNP. The wells were washed three times with PBS between each incubation for all binding assays. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.

2.5. Binding of r β_2 GPI to Cardiolipin (CL)

The binding of r β_2 GPI to CL was performed by CL-ELISA as previously described [28]. Briefly, 96 well vinyl microtiter plates (Costar) were coated with 30 μ l of CL solution in ethanol (50 μ g/ml) (Sigma). The plates were dried under vacuum and blocked with PBS containing 1% milk and 0.3% gelatin at 25°C for 1 hr. The plates were washed three times with PBS and incubated with 50 μ l of serum-free-cell-free culture media of transfected COS-1 cells containing r β_2 GPI at 25°C for 3 hrs. The bound r β_2 GPI was detected by polyclonal rabbit anti- β_2 GPI antiserum (Alexis Corp.) (0.5 μ g/ml in PBS containing 1% BSA) followed by alkaline phosphatase conjugated goat anti-rabbit IgG antiserum (Instar Corp.). Each reaction was incubated at 37°C for 90 minutes followed by addition of 100 μ l of PNP. The color intensity was measured as optical density (OD) at 410 nm after different time intervals.

2.6. Competition Assays

A competition assay was performed in which CL coated microtiter wells were incubated with 50 μ l of serum-free-cell-free culture media from transfected COS-1 cells containing r β_2 GPI at 25°C for 3 hrs followed by three washings with PBS. The CL-bound r β_2 GPI was then allowed to bind to the increasing amount of rHBsAg (rS,L* particles, 0.31 to 10 μ g/well diluted in PBS containing 1% BSA) and the bound rHBsAg was detected by anti-HBs antiserum (DAKO Corp.) as described above. Control wells received no rHBsAg. The CL-bound r β_2 GPI was detected with polyclonal rabbit anti- β_2 GPI antiserum, as described above. A control assay was also performed where r β_2 GPI captured by anti- β_2 GPI mAb coated microtiter wells were allowed to bind to increasing amounts of rHBsAg (rS,L* particles, 0.31 to 10 μ g/well diluted in PBS containing 1% BSA) and the bound rHBsAg was detected by anti-HBs antiserum, as described above.

3. Results

3.1. Effect of the Cys306Gly and Trp316Ser Mutations on rHBsAg Binding

Figure 1 shows the secreted levels of wild-type and mutant r β_2 GPI into the serum-free-cell-free culture media of the transfected COS-1 cells and the binding of r β_2 GPI wild and mutant types to rHBsAg or CL. While the levels of wild-type and mutant r β_2 GPI secreted into the culture media were comparable (solid bars), the binding of r β_2 GPI mutants (Gly306, Ser316, and Gly306/Ser316) to rHBsAg were significantly reduced as compared to the wild-type r β_2 GPI (dark bars). The isoform-specific binding of r β_2 GPI with rHBsAg (dark bars) was similar to that observed for the CL-r β_2 GPI binding (light bars). These results show that a single mutation either at codon 306 or 316 in the fifth

domain of β_2 GPI is sufficient to disrupt the interaction of $r\beta_2$ GPI with either rHBsAg or CL.

Insert Figure 1 about here

3.2. Effect of Hydrophobic Amino Acids at Positions 313-316 on rHBsAg Binding

In addition to the naturally occurring Trp316Ser mutation, we changed the remaining three conserved hydrophobic amino acids at positions 313-315 to neutral amino acids (Leu313Gly, Ala314Ser and Phe315Ser) in β_2 GPI cDNA by site-directed mutagenesis, expressed them in COS-1 cells, and examined the binding of the mutant-type $r\beta_2$ GPI with rHBsAg or CL (Fig. 2). While Ala314Ser had no effect on the binding of $r\beta_2$ GPI with rHBsAg (92%; dark bars) or CL (106%; light bars), the Leu313Gly and Phe315Ser mutations significantly reduced the binding of mutant $r\beta_2$ GPI with rHBsAg (38% and 9% of the wild-type $r\beta_2$ GPI, respectively; dark bars) as well as with CL (25% and 13% of the wild-type $r\beta_2$ GPI, respectively; light bars). However, the levels of $r\beta_2$ GPI secreted into the serum-free-cell-free culture media of the wild-type and each mutant β_2 GPI cDNA transfected COS-1 cells were comparable (solid bars). The results from these experiments further demonstrate that rHBsAg and CL share same binding region on the β_2 GPI molecules.

Insert Figure 2 about here

3.3. Competition Between rHBsAg and CL for Binding to β_2 GPI

To confirm our findings that rHBsAg and CL bind to the same region on β_2 GPI, we

performed two competition assays. In the first assay, CL-bound $r\beta_2$ GPI on microtiter wells was allowed to bind with an increasing amount of rHBsAg (0.31 to 10 μ g/well) (Fig. 3A). As expected, CL-bound $r\beta_2$ GPI exhibited no binding with rHBsAg, as the binding site for rHBsAg on β_2 GPI was blocked by CL. These results suggest that the binding of $r\beta_2$ GPI to CL is saturated with higher affinity than with rHBsAg because the addition of increasing amounts of rHBsAg did not affect $r\beta_2$ GPI-CL binding. A second assay was designed to test whether steric hindrance or steric resistance is the reason for lack of binding of rHBsAg to $r\beta_2$ GPI-CL complex. In this experiment, $r\beta_2$ GPI captured by anti- β_2 GPI mAb on microtiter wells was incubated with increasing amounts of rHBsAg (Fig. 3B). The rHBsAg binding to the mAb-captured $r\beta_2$ GPI increased with increasing amount of rHBsAg added (Fig. 3B) as opposed to CL bound $r\beta_2$ GPI, which demonstrated no binding to rHBsAg even at highest concentration (Fig. 3A). This suggests that the binding sites for rHBsAg (or CL) and mAb on β_2 GPI are different and thus steric hindrance caused by the mAb is not a factor.

Insert Figure 3 about here

4. Discussion

The mechanism of HBV entry and its cellular receptor on the surface of human hepatocytes are not well understood. However, several candidate receptors have been identified that includes β_2 GPI, which was first reported by us [6,7] and latter by others [33-35]. β_2 GPI is a secretory glycoprotein that is present in plasma in association with several lipoprotein particles as well as in lipid-free form [9,10,22]. Since β_2 GPI is not a transmembrane protein, a typical criterion for a viral receptor, we have earlier

hypothesized that β_2 GPI present on the surface of lipoprotein particles might serve as a receptor for HBV and that the lipoprotein-HBV complex enters hepatocytes during the process of lipoprotein uptakes [6]. Although the experimental data supporting this hypothesis is lacking at present, here we have addressed several critical questions regarding the interaction between β_2 GPI and HBV.

Previously, we demonstrated that the binding of β_2 GPI with rHBsAg was disrupted by reducing the intramolecular disulfide bonds of β_2 GPI [6] and chemical modification of as few as three positively charged lysine residues of β_2 GPI [7]. However, this interaction was not affected by the removal of β_2 GPI carbohydrate side chains or chemical modification of arginine, the other positively charged amino acid [7]. These results suggested that the interaction between β_2 GPI and rHBsAg was most likely due to protein-protein interaction. On the other hand, Neurath and Strick [36] have suggested that since delipidation of rHBsAg abolishes β_2 GP1-rHBsAg binding, that the lipid moiety of rHBsAg is involved in binding β_2 GPI. Subsequently, Stefas et al. [35] have demonstrated that the myristylated pre-S1 domain of HBsAg strongly interacted with β_2 GPI, which involved PL component of HBV envelope because the removal of PL component by detergent or oxidation prevented β_2 GPI-HBsAg interaction. Notwithstanding whether it is the lipid or protein moiety of rHBsAg that binds to β_2 GPI, the β_2 GPI domain that binds to rHBsAg is not known.

A robust way to localize the binding domain of β_2 GPI is to assess the role of naturally occurring or artificially created missense mutations of β_2 GPI in binding rHBsAg. We

identified two naturally occurring missense mutations, Cys306Gly and Trp316Ser in the fifth domain of β_2 GPI that disrupt PL binding to β_2 GPI [27,28]. The Cys306Gly mutation disrupts a disulfide bond between Cys306 and Cys281, which is critical for clustering several lysine residues [15]. The Trp316Ser mutation disrupts the integrity of an evolutionarily conserved hydrophobic amino acid sequence at positions 313-316 [15]. We hypothesized that these mutations would also disrupt β_2 GPI-rHBsAg binding. Indeed our data demonstrate that the mutant r β_2 GPI carrying one or both mutations do not bind to rHBsAg. These results show that rHBsAg and anionic PL share the same binding region on the β_2 GPI molecule. To further identify or discriminate between the binding sites of rHBsAg and anionic PL on β_2 GPI, we examined the effect of the remaining evolutionarily conserved hydrophobic amino acids in the vicinity of the Trp316Ser mutation at positions 313-315 on the ability of β_2 GPI to bind rHBsAg. Three hydrophobic amino acids at positions 313-315 were mutated to neutral residues (Leu313Gly, Ala314Ser and Phe315Ser) and the mutant r β_2 GPI were then allowed to bind rHBsAg or CL. The Leu313Gly and Phe315Ser mutations significantly reduced the binding of mutant r β_2 GPI to both rHBsAg and CL, while the Ala314Ser mutation showed normal binding with both rHBsAg and CL. These results indicate that the binding of β_2 GPI to rHBsAg or CL involves both ionic (shown by the Cys306Gly mutation, which disrupts the clustering of lysine residues of the fifth domain) and hydrophobic (shown by the mutagenized 313-316 sequence) interactions.

Further evidence that rHBsAg and CL share a binding region on β_2 GPI comes from our competition assay in which r β_2 GPI bound to CL-coated microtiter wells was allowed to

bind to increasing amounts of rHBsAg. If CL and rHBsAg share same binding region on r β_2 GPI then CL-bound r β_2 GPI would not be able to bind rHBsAg. Indeed, we found that r β_2 GPI bound to CL was unable to bind rHBsAg. This suggests that rHBsAg and CL compete for the same binding region on r β_2 GPI. Although it is possible that the r β_2 GPI bound to the well via CL might be in the correct orientation to bind to rHBsAg if the two binding regions on r β_2 GPI were different as in case of anti- β_2 GPI antibodies (the mAb) which did bind to CL-bound r β_2 GPI.

Our results on rHBsAg binding with β_2 GPI using the naturally occurring mutations as well as artificially created mutations in the lipid-binding region of β_2 GPI suggest that the lipid (PL) rather than the protein moiety of rHBsAg binds to r β_2 GPI, as originally suggested by Neurath and Strick [36] and latter by Stefas et al. [35]. The Cys306Gly mutation in the fifth domain of β_2 GPI disrupts the clustering of lysine residues, which are required for ionic binding with PL. Likewise, the fifth domain is necessary for the hydrophobic binding with PL [37-39]. Since mutations at this region also disrupt the binding of β_2 GPI with rHBsAg, it appears that the lipid moiety, perhaps anionic PL, rather than the protein moiety of rHBsAg, is involved in binding with β_2 GPI. Indirect support to the hypothesis that the lipid moiety of rHBsAg binds to the lipid-binding region in the fifth domain of β_2 GPI comes from another competition assay where the r β_2 GPI captured by anti- β_2 GPI mAb on coated microtiter wells was able to bind to rHBsAg. This indicates that while the lipid moiety of rHBsAg binds to the lipid-binding region in the fifth domain of β_2 GPI, the commercially available anti- β_2 GPI mAb binds to a different domain of β_2 GPI but the r β_2 GPI-CL complex could not bind rHBsAg confirming that the CL and rHBsAg bind to the same region on r β_2 GPI.

In summary, we have identified the binding region for rHBsAg on β_2 GPI, which is located in the fifth domain of β_2 GPI and it appears to be the same as PL-binding region on β_2 GPI. Our results in conjunction with the observation of Neurath and Strick [36] and Stefas et al., [35] indicate that rHBsAg binds to β_2 GPI through its lipid moiety. These results also confirm our previous reports that the interaction between rHBsAg and β_2 GPI is strong and saturable [6,7].

Acknowledgements

We thank Dr. Tineke Rutgers, Dmith Kline-Beachem for the rHBsAg and Dr. Mark E. Peebles, Rush University for providing β_2 GPI cDNA and critically reviewing our manuscript. This work was supported by a National Heart, Lung, and Blood Institute (NHLBI) grant HL 54900.

References

- [1] J. Summers, J. Smolec, R. Snyder R, A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchuck, Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 4533-4537.
- [2] P.L. Marion, L.S. Oshiro, D.C. ReQnery, G.H. Scullard, W.S. Robinson, A virus in Beechey ground squirrels which is related to hepatitis B virus of man, Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 2941-2945.
- [3] W.S. Mason, S. Seal, J. Summers, Virus Peking ducks with structurally and biologically relatedness to human hepatitis B virus, J. Virol. 36 (1980) 829-836.
- [4] R. Sprengel, E. F. Kaleta, H. Will, Isolation and characterization of a hepatitis B virus endemic in herons, J. Virol. 52 (1988) 3832-3839.
- [5] J. Summers, Three recently described animal virus models for human hepatitis B virus, Hepatology 1 (1981) 179-183.
- [6] H. Mehdi, M.J. Kaplan, F.Y. Anlar, X. Yang, R. Bayer, K. Sutherland, M.E. Peeples, Hepatitis B virus surface antigen binds to apolipoprotein H, J. Virol. 68 (1994) 2415-2424.
- [7] H. Mehdi, X. Yang, M.E. Peeples, An altered form of apolipoprotein H binds hepatitis B virus surface antigen most efficiently, Virology 217 (1996) 58-66.
- [8] H.E. Schultz, K. Heide, H. Haupt, Uber ein bisher unbekanntes neidermolekul es β_2 -Globulin des Humanserums, Naturwissenschaften 48 (1961) 719.
- [9] E. Polz, G.M. Kostner, The binding of β_2 -glycoprotein I to human serum lipoproteins: Distribution among density fractions. FEBS Lett. 102 (1979) 183-186.
- [10] E. Polz, G.M. Kostner, Binding of β_2 -glycoprotein I to intralipid: Distribution of the

- dissociation constant, *Biochem. Biophys. Res. Commun.* 90 (1979) 1305-1312.
- [11] Y. Hasunuma, E. Matsuura, Z. Makita, T. Katahira, S. Nishi, T. Koike, Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages, *Clin. Exp. Immunol.* 107 (1997) 569-573.
- [12] S. Hörkkö, E. Miller, D.W. Branch, W. Palinski, J.L. Witztum, The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins), *Proc. Natl. Acad. Sci. U.S.A.* 94 (1997) 10356-10361.
- [13] K.Y. Lin, J.P. Pan, D.L. Yang, K.T. Huang, M.S. Chang, P.Y. Ding, A.N. Chiang, Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I), *Life Sci.* 69 (2001) 707-719.
- [14] T. Kristensen, I. Schousboe, E. Boel, E.M. Mulvihill, R.R. Hansen, K.B. Moller, N.P.H. Moller, L. Sottrup-Jensen L, Molecular cloning and mammalian expression of human β_2 -glycoprotein I cDNA, *FEBS Lett.* 289 (1991) 183-186.
- [15] J. Lozier, N. Takahashi, F.W. Putnam, Complete amino acid sequence of human plasmid β_2 -glycoprotein I, *Proc. Natl. Acad. Sci. U.S.A.* 81 (1984) 3640-3644.
- [16] H. Mehdi, M. Nunn, D.M. Steel, A.S. Whitehead, M. Perez, L. Walker, M.E. Peeples, Nucleotide sequence and expression of the human gene encoding apolipoprotein H, *Gene* 108 (1991) 293-298.
- [17] A. Steinkasserer, C. Estaller, E. Weiss, R.B. Sim, Complete nucleotide and deduced amino acid sequence of human β_2 -glycoprotein I, *Biochem. J.* 277 (1991) 387-391.

- [18] H. Kato, K.I. Enyoji KI, Amino acid sequence and location of the disulfide bonds in bovine β_2 -glycoprotein I: The presence of five sushi domains, *Biochemistry* 30 (1991) 1687-1694.
- [19] Y. Aoyama, Y.L. Chan, I.G. Wool, The primary structure of rat β_2 glycoprotein I, *Nucl. Acid. Res.* 17 (1989) 6401.
- [20] M. Nonaka, Y. Matsuda, T. Shirojshi, K. Moriwaki, M. Nonaka, S. Natsuume-Sakai, Molecular cloning of mouse β_2 -glycoprotein I and mapping of the gene to chromosome 11, *Genomics* 13 (1992) 1082-1087.
- [21] G.C. Sellar, J. Keane, H. Mehdi, M.E. Peeoles, N. Browne, A.S. Whitehead AS, Characterization and acute phase modulation of canine apolipoprotein H (β_2 -glycoprotein I), *Biochem. Biophys. Res. Commun.* 191 (1993) 1288-1293.
- [22] H. Wurm H, β_2 -glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. *Int. J. Biochem.* 16 (1984) 511-515.
- [23] J.V. Jones, H. James, M.H. Tan, M. Mansouor, Antiphospholipid antibodies required β_2 -glycoprotein I (apolipoprotein H) as cofactor, *J. Rheumatol.* 19 (1992) 1397-1402.
- [24] H.P. McNeil, R.J. Simpson, C.N. Chesterman, S.A. Krilis, Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: r β_2 -glycoprotein I (apolipoprotein H), *Proc. Natl. Acad. Sci. U.S.A.* 87 (1990) 4120-4124.
- [25] D.K. Sanghera, T. Kristensen, R.F. Hamman, M.I. Kamboh, Molecular basis of the apolipoprotein H (β_2 -glycoprotein I) protein polymorphism, *Hum. Genet.* 100 (1997) 57-62.

- [26] A. Steinkasserer, C. Dorner, R. Wurzner, R.B. Sim, Human β_2 -glycoprotein I: molecular analysis of DNA and amino acid polymorphism, *Hum. Genet.* 91 (1993) 401-402.
- [27] D.K. Sanghera, D.R. Wagenknecht, J.A. McIntyre, M.I. Kamboh, Identification of structural mutations in the fifth domain of apolipoprotein H (β_2 glycoprotein I) which affect phospholipid binding, *Hum. Mol. Genet.* 6 (1997) 311-316.
- [28] H. Mehdi, A. Naqvi, M.I. Kamboh, A hydrophobic sequence at position 313316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (β_2 -glycoprotein I) is crucial for cardiolipin binding, *Eur. J. Biochem.* 267 (2000) 1770-1776.
- [29] F. Sanger, S. Nicklin, A.R. Coulson, DNA sequencing with chain-terminating inhibitors, *Proc. Natl. Acad. Sci. U.S.A.* 74 (1977) 5463-5467.
- [30] H. Mehdi, E. Ono, K.C. Gupta, Initiation of translation at CUG, GUG, and ACG codons in mammalian cells, *Gene* 91 (1990) 173-178.
- [31] A. Miyanochara, A. Toh-e, C. Nozaiki, F. Hamada, N. Ohtomo, K. Matsubara, Expression of hepatitis B surface antigen gene in yeast. *Proc. Natl. Acad. Sci. U.S.A.* 80 (1993) 1-5.
- [32] P. Valenzuela, A. Medina, W.J. Rutter, G. Ammerer, B.D. Hall, Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. *Nature* 298 (1982) 347-350.
- [33] P.J. Gao, Y.F. Piao, X.D. Liu, L.K. Qu, Y. Shi, X.C. Wang, H.Y. Tang, Studies on specific interaction of beta-2-glycoprotein I with HBsAg. *World J. Gastroenterol.* 9 (2003) 2114-2116.
- [34] P.J. Gao, Y. Shi, Y.H. Gao, Y.W. Liu, Y. Tang, The receptor β_2 GPI on membrane

- of hepatocellular carcinoma cell line SMMC-7721 is annexin II. *World J. Gastroenterol.* 13 (2007) 3364-3368.
- [35] I. Stefas, M. Rucheton, A.D. D'Angeac, C. Morel-Baccard, J.M. Seigneurin, J.P. Zarski, M. Martin, M. Cerutti, J.P. Bossy, D. Misse, H. Graafland, F. Veas, Hepatitis B virus Dane particles bind to human plasma apolipoprotein H. *Hepatology* 33 (2001) 207-217.
- [36] A.R. Neurath, N. Strick, The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV, *Virology* 204 (1994) 475-477.
- [37] B. Bouma, P.G. de Groot, J.M.H. van den Elsen, R.B.G. Ravelli, A. Schouten, M.J.A. Simmelink, R.H.W.M. Derksen, J. Kroon, P. Gras, Adhesion mechanism of human β_2 -glycoprotein I to phospholipids based on its crystal structure, *EMBO J.* 18 (1999) 5166-5174.
- [38] R. Schwarzenbacher, K. Zeth, K. Diedericks, A. Gries, G.M. Kostner, P. Laggner, R. Prassl, Crystal structure of human β_2 -glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome, *EMBO J.* 18 (1999) 6228-6239.
- [39] M. Hoshino, Y. Hagihara, I. Nishii, T. Yamazaki, H. Kato, Y. Goto, Identification of the phospholipid-binding site of human beta(2)-glycoprotein I domain V by heteronuclear magnetic resonance, *J. Mol. Biol.* 304 (2000) 927-939.

Figure Legends

Fig. 1: Effect of naturally occurring missense mutations in the fifth domain of β_2 GPI (Cys306Gly and Trp316Ser) on its ability to bind to rHBsAg and CL.

The r β_2 GPI secreted into the culture medium of mock, wild-type, Gly306 mutant, Ser316 mutant and Gly306/Ser316 double mutant transfected COS-1 cells was quantitated by capture ELISA (■). The secreted wild-type and mutant-type r β_2 GPI were then allowed to bind to rHBsAg (▣) or CL (▤) on microtiter plates to examine the effect of these mutations on the ability of r β_2 GPI to bind to rHBsAg or CL. Results are given as mean \pm SD from three independent clones in triplicate (n=9).

Fig. 2: Effect of hydrophobic amino acids in the fifth domain of r β_2 GPI at positions 313-316 on its ability to bind to rHBsAg and CL. Four hydrophobic amino acids at positions 313-316 were mutated to neutral amino acids (Trp316Ser, Phe315Ser, Ala314Ser and Leu313Gly) and expressed in COS-1 cells. The secreted r β_2 GPI forms were quantitated by capture ELISA (■) followed by their binding to rHBsAg (▣) or CL (▤). Results are given as mean \pm SD from three independent clones in triplicate (n=9).

Fig. 3: Competition assay. (A) Microtiter wells coated with CL were allowed to bind to r β_2 GPI and then incubated for 16 hrs with increasing amount rHBsAg. (B) Microtiter wells coated with anti- β_2 GPI were allowed to bind to r β_2 GPI followed by binding to increasing amount rHBsAg. Results are given as mean \pm SD from three independent experiments in triplicate (n=9).

Figures




Figure 1

ACC




Figure 2




Figure 3A

ACC




Figure 3B

ACC